Anti-anginal drugs: Systematic review and clinical implications

INTERNATIONAL JOURNAL OF CARDIOLOGY

卷:283

Review

Pavasini, Rita¹  Camici, Paolo G.^2,3  Crea, Filippo⁴  Danchin, Nicolas⁵  Fox, Kim^6,7  Manolis, Athanasios J.⁸  Marzilli, Mario^9,10  Rosano, Giuseppe M. C.^11,12  Lopez-Sendon, Jose L.¹³  Pinto, Fausto¹⁴  Balla, Cristina¹  Ferrari, Roberto^1,15 

[1] Univ Hosp Ferrara, Ctr Cardiol Univ, Via Aldo Moro 8, I-44124 Ferrara, Italy

[2] Univ Vita Salute San Raffaele, Via Olgettina Milano 58-60, I-20132 Milan, Italy

[3] Osped San Raffaele, Via Olgettina Milano 58-60, I-20132 Milan, Italy

[4] Catholic Univ, Dept Cardiovasc & Thorac Sci, Largo Francesco Vito 1, I-00168 Rome, Italy

[5] European Hosp Georges Pompidiou, Cardiol, 20 Rue Leblanc, F-75015 Paris, France

[6] Imperial Coll, Natl Heart & Lung Inst, Sydney St, London SW3 6NP, England

[7] Royal Brompton Hosp, Inst Cardiovasc Med & Sci, Sydney St, London SW3 6NP, England

[8] Asklepe Gen Hosp, Dept Cardiol, 1 Vas Pavlou St, Athens 16673, Greece

[9] Cardiothorac Dept, Lungarno Antonio Pacinotti 43, I-56126 Pisa, Italy

[10] Osped Riuniti Valdichiana Sudest, Nottola Cardiol Div, I-53045 Siena, Italy

[11] St Georges Hosp NHS Trust, Clin Acad Grp, Blackshaw Rd, London SW17 0QT, England

[12] IRCCS San Raffaele, Dept Med Sci, Via Pisana 235, I-00163 Rome, Italy

[13] Hosp Univ La Paz, Dept Cardiol, IdiPaz, Paseo Castellana 261, Madrid 28036, Spain

[14] Univ Lisbon, Hosp Univ Santa Maria, Ctr Hosp Lisboa Norte, Ctr Cardiovasc,Ctr Acad Med Lisboa,Fac Med, Lisbon, Portugal

[15] Maria Cecilia Hosp, GVM Care & Res, Via Corriera 1, Cotignola, RA, Italy

关键词: Beta-blockers;    Ivabradine;    Stable angina;    Calcium channel blockers;    Ranolazine;    Trimetazidine;   

DOI  :  10.1016/j.ijcard.2018.12.008

来源: Elsevier

【 摘 要 】

Background: The cornerstone of the treatment of patients affected by stable angina is based on drugs administration classified as first (beta-blockers, calcium channel blockers, short acting nitrates) or second line treatment (long-acting nitrates, ivabradine, nicorandil, ranolazine and trimetazidine). However, few data on comparison between different classes of drugs justify that one class of drugs is superior to another. Methods: We performed a systematic review of the literature following PRISMA guidelines. Inclusion criteria: i) paper published in English; ii) diagnosis of stable coronary disease; iii) randomized clinical trial; iv) comparison of two anti-angina drugs; v) a sample size >100 patients; vi) a follow-up lasting at least 2 weeks; vii) paper published after 1999, when a meta-analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina of Heidenreich et al. was published. Outcome: to establish whether the categorization in first and second line antianginal treatment is scientifically supported. Results: Eleven trials fulfilled inclusion criteria. The results show that there is a paucity of data comparing the efficacy of antianginal agents. The little data available show that there are not compounds superior to others in terms of improvement in exercise test duration, frequency of anginal attacks, need for sub-lingual nitroglycerin. Conclusion: The categorization of antianginal drug in first and second line is not confirmed. (c) 2018 Elsevier B.V. All rights reserved.

【 授权许可】

Free